Rocket Pharmaceuticals Inc. (RCKT) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rocket Pharmaceuticals In...

    NASDAQ: RCKT · Real-Time Price · USD
    3.26
    0.07 (2.19%)
    At close: Sep 26, 2025, 3:59 PM
    3.25
    -0.44%
    After-hours: Sep 26, 2025, 06:08 PM EDT

    Rocket Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 9.38M 7.1M 6.27M 5.37M
    Gross Profit
    		 -9.38M -7.1M -6.27M -5.37M
    Operating Income
    		 -273.2M -259.66M -224.34M -167.25M
    Interest Income
    		 18.22M 15.94M 3.89M 3.07M
    Pretax Income
    		 -258.75M -245.59M -221.86M -169.07M
    Net Income
    		 -258.75M -245.59M -219.38M -169.59M
    Selling & General & Admin
    		 101.96M 71.59M 58.77M 41.77M
    Research & Development
    		 171.24M 180.97M 165.57M 125.48M
    Other Expenses
    		 n/a n/a -500K n/a
    Operating Expenses
    		 273.2M 252.56M 223.84M 167.25M
    Interest Expense
    		 1.89M 1.88M 1.91M 5.89M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 273.2M 259.66M 223.84M 167.25M
    Income Tax Expense
    		 n/a n/a -2.48M 516K
    Shares Outstanding (Basic)
    		 94.81M 84.01M 68.15M 63.24M
    Shares Outstanding (Diluted)
    		 94.81M 84.01M 68.15M 63.24M
    EPS (Basic)
    		 -2.73 -2.92 -3.26 -2.68
    EPS (Diluted)
    		 -2.73 -2.92 -3.26 -2.68
    EBITDA
    		 -247.49M -236.62M -213.69M -161.72M
    EBIT
    		 -256.86M -243.72M -220.5M -167.09M
    Depreciation & Amortization
    		 9.38M 7.1M 6.27M 5.37M

    Add to Watchlist